Stability, pKa and plasma protein binding of roscovitine

被引:42
作者
Vita, M [1 ]
Abdel-Rehim, M
Nilsson, C
Hassan, Z
Skansen, P
Wan, H
Meurling, L
Hassan, M
机构
[1] Karolinska Univ Hosp, Dept Med, Div Hematol, Hematol Lab, S-14186 Huddinge, Sweden
[2] AstraZeneca, S-15185 Sodertalje, Sweden
[3] AstraZeneca R&D, DMPK & Bioanalyt Chem, S-43183 Molndal, Sweden
[4] Karolinska Univ Hosp, TDM Lab, Dept Lab Med, Div Clin Pharmacol, S-14186 Huddinge, Sweden
来源
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES | 2005年 / 821卷 / 01期
关键词
LC-MS-MS; equilibrium dialysis; ultrafiltration; pKa; olomoucine; alpha 1-acid glycoprotein;
D O I
10.1016/j.jchromb.2005.04.014
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
In the present investigation, the binding of roscovitine (100, 500 and 1500 ng/mL) to plasma proteins was studied at 25 and 37 degrees C by ultratiltration and equilibrium dialysis methods. Drug stability in plasma was assessed during a 48 h at 4, 25 and 37 degrees C. The effect of thawing and freezing on drug stability was studied. The pKa of roscovitine was measured using capillary electrophoresis coupled with mass spectrometry. Roscovitine was quantified utilizing liquid chromatography and tandem mass spectrometry. Roscovitine is highly bound to plasma proteins (90%). Binding of roscovitine to human serum albumin was constant (about 90%) within concentration range studied while the binding to alpha 1-acid glycoprotein decreased with increasing drug concentration indicating that albumin is more important in clinical settings. However, alpha 1-acid glycoprotein might be important when plasma proteins change with disease. Protein binding was higher at 25 degrees C compared to 37 degrees C. The results obtained by equilibrium dialysis were in good agreement with those obtained by ultrafiltration. Roscovitine was stable at all temperatures studied during 48 h. Roscovitine has a pKa of 4.4 showing that the drug mainly acts like a weak mono-base. ne results obtained in our studies are important prior to clinical trials and to perform phannacokinetic studies. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:75 / 80
页数:6
相关论文
共 38 条
  • [1] Evaluation of solid-phase microextraction for the study of protein binding in human plasma samples
    Abdel-Rehim, M
    Carlsson, G
    Bielenstein, M
    Arvidsson, T
    Blomberg, LG
    [J]. JOURNAL OF CHROMATOGRAPHIC SCIENCE, 2000, 38 (10) : 458 - 464
  • [2] ALBERTIONI F, 1994, EUR J CLIN PHARMACOL, V46, P563
  • [3] Development and validation of a 96-well equilibrium dialysis apparatus for measuring plasma protein binding
    Banker, MJ
    Clark, TH
    Williams, JA
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 2003, 92 (05) : 967 - 974
  • [4] PRAZOSIN BINDING TO HUMAN ALPHA-1-ACID GLYCOPROTEIN (OROSOMUCOID), HUMAN-SERUM ALBUMIN, AND HUMAN-SERUM - FURTHER CHARACTERIZATION OF THE SINGLE DRUG-BINDING SITE OF OROSOMUCOID
    BRUNNER, F
    MULLER, WE
    [J]. JOURNAL OF PHARMACY AND PHARMACOLOGY, 1985, 37 (05) : 305 - 309
  • [5] de la Motte S, 2004, INT J CLIN PHARM TH, V42, P232
  • [6] Inhibition of cyclin-dependent kinases by purine analogues - Crystal structure of human cdk2 complexed with roscovitine
    DeAzevedo, WF
    Leclerc, S
    Meijer, L
    Havlicek, L
    Strnad, M
    Kim, SH
    [J]. EUROPEAN JOURNAL OF BIOCHEMISTRY, 1997, 243 (1-2): : 518 - 526
  • [7] EHRNEBO M, 1974, CLIN PHARMACOL THER, V16, P424
  • [8] BINDING OF BUSULFAN TO PLASMA-PROTEINS AND BLOOD-CELLS
    EHRSSON, H
    HASSAN, M
    [J]. JOURNAL OF PHARMACY AND PHARMACOLOGY, 1984, 36 (10) : 694 - 696
  • [9] Reversal of collapsing glomerulopathy in mice with the cyclin-dependent kinase inhibitor CYC202
    Gherardi, D
    D'Agati, V
    Chu, THT
    Barnett, A
    Gianella-Borradori, A
    Gelman, IH
    Nelson, PJ
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2004, 15 (05): : 1212 - 1222
  • [10] HAHNTOW IN, 2004, LEUKEMIA, P1